Department of Anesthesiology and Pain Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Korean J Anesthesiol. 2020 Oct;73(5):434-444. doi: 10.4097/kja.19481. Epub 2020 Feb 12.
Studies investigating the correlation between spinal adenosine A1 receptors and vincristine-induced peripheral neuropathy (VIPN) are limited. This study explored the role of intrathecal N6-(2-phenylisopropyl)-adenosine R-(-)isomer (R-PIA) in the rat model of VIPN.
Vincristine (100 μg/kg) was intraperitoneally administered for 10 days (two 5-day cycles with a 2-day pause) and VIPN was induced in rats. Pain was assessed by evaluating mechanical hyperalgesia, mechanical dynamic allodynia, thermal hyperalgesia, cold allodynia, and mechanical static allodynia. Biochemically, tumor necrosis factor-alpha (TNF-α) level and myeloperoxidase (MPO) activity were measured in the tissue from beneath the sciatic nerve.
Vincristine administration resulted in the development of cold allodynia, mechanical hyperalgesia, thermal hyperalgesia, mechanical dynamic allodynia, and mechanical static allodynia. Intrathecally administered R-PIA (1.0 and 3.0 μg/10 μl) reversed vincristine-induced neuropathic pain (cold and mechanical static allodynia). The attenuating effect peaked 15 min after intrathecal administration of R-PIA after which it decreased until 180 min. However, pretreatment with 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, 10 μg/10 μl) 15 min before intrathecal R-PIA administration significantly attenuated the antiallodynic effect of R-PIA. This antiallodynic effect of intrathecal R-PIA may be mediated through adenosine A1 receptors in the spinal cord. Intrathecally administered R-PIA also attenuated vincristine-induced increases in TNF-α level and MPO activity. However, pretreatment with intrathecal DPCPX significantly reversed this attenuation.
These results suggest that intrathecally administered R-PIA attenuates cold and mechanical static allodynia in a rat model of VIPN, partially due to its anti-inflammatory actions.
研究脊髓腺苷 A1 受体与长春新碱诱导的周围神经病变(VIPN)之间相关性的研究有限。本研究探讨了鞘内 N6-(2-苯基异丙基)-腺苷 R-(-)异构体(R-PIA)在 VIPN 大鼠模型中的作用。
长春新碱(100μg/kg)腹腔内给药 10 天(两个 5 天周期,间隔 2 天),诱导大鼠 VIPN。通过评估机械性超敏反应、机械性动态痛觉过敏、热痛觉过敏、冷性痛觉过敏和机械性静态痛觉过敏来评估疼痛。生物化学方面,测量坐骨神经下方组织中的肿瘤坏死因子-α(TNF-α)水平和髓过氧化物酶(MPO)活性。
长春新碱给药导致冷性痛觉过敏、机械性超敏反应、热痛觉过敏、机械性动态痛觉过敏和机械性静态痛觉过敏的发生。鞘内给予 R-PIA(1.0 和 3.0μg/10μl)逆转了长春新碱诱导的神经病理性疼痛(冷性和机械性静态痛觉过敏)。鞘内给予 R-PIA 15 分钟后达到峰值,之后直至 180 分钟逐渐减弱。然而,在鞘内给予 R-PIA 之前 15 分钟预先给予 1,3-二丙基-8-环戊基黄嘌呤(DPCPX,10μg/10μl)显著减弱了 R-PIA 的抗痛觉过敏作用。鞘内给予 R-PIA 的这种抗痛觉过敏作用可能是通过脊髓中的腺苷 A1 受体介导的。鞘内给予 R-PIA 还减弱了长春新碱诱导的 TNF-α水平和 MPO 活性的增加。然而,鞘内预先给予 DPCPX 显著逆转了这种减弱作用。
这些结果表明,鞘内给予 R-PIA 减轻了 VIPN 大鼠模型中的冷性和机械性静态痛觉过敏,部分原因是其抗炎作用。